Management of hyperglycemia with oral antihyperglycemic agents in type 2 diabetes

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 687-710

  Lebovitz, Harold E ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970952280     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (163)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. . Engl J Med 1993;329:977-986.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
3. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865.
4. Dostou J, Gerich J. Pathogenesis of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2001;109[Suppl 2]:S149-S156.
5. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1998;37:1595-1607.
6. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulindependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19: 477-490.
7. Shulman GI. Cellular mechanisms of insulin resistance. . Clin Invest 2000;106: 171-176.
8. van Haeften TW, Pimenta W, Mitrakou A, et al. Relative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucoseload glycemia. Metabolism 2000;49:1318-1325.
9. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus. . Engl J Med 1998; 338:867-872.
10. Hanefeld M, Dickinson S, Bouter KP, et al. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000;23:202-207.
11. Lebovitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132-145.
12. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249-1258.
13. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001;30:909-933.
14. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 2002;287:360-372.
15. Lebovitz HE. Effects of oral antidiabetic agents in modifying macrovascular risk factors in type 2 diabetes. Diabetes Care 1999;22[Suppl 3]:C41-C44.
16. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
17. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-1298.
18. Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
19. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. . Engl J Med 1992;326:22-29.
20. Roden M, Petersen KF, Shulman GI. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog Horm Res 2001;56: 219-237.
21. Newsholme EA, Dimitriadis G. Integration of biochemical and physiologic effects of insulin on glucose metabolism. Exp Clin Endocrinol Diabetes 2001; 109[Suppl 2]:S122-S134.
22. Gavin JR. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 2001;88[Suppl]:4H-8H.
23. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-819.
24. Haller H. The clinical importance of postprandial glucose. Diabetes Res Clin Pract 1998;40[Suppl]:S43-S49.
25. Ceriello A, Lizzio S, Bortolotti N, et al. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 1998;21:1529-1533.
26. Ratner RE. Controlling postprandial hyperglycemia. Am J Cardiol 2001;88 [Suppl]:26H-31H.
27. Bastyr EJ 3rd, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000;23:1236-1241.
28. Stern MP, Morales PA, Valdez RA, et al. Predicting diabetes. Moving beyond impaired glucose tolerance. Diabetes 1993;42:706-714.
29. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001;109[Suppl 2]:S135-S148.
30. Bavdekar A, Chittaranjan S, Yajnik S, et al. Insulin resistance syndrome in 8-year-old Indian children. Diabetes 1999;48:2422-2429.
31. Gerich JE. The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.
32. Brunzell JD, Robertson RP, Lerner RL, et al. Relationships between fasting glucose levels and insulin secretion during intravenous glucose tolerance tests. . Clin Endocrinol Metab 1976;42:222-229.
33. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
34. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
35. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
36. Stern M. The Insulin Resistance Syndrome. In: Alberti KGMM, Zimmet P, DeFronzo RA, Keen H, eds. International textbook of diabetes mellitus, 2nd ed. Chichester, UK: John Wiley & Sons; 1997:255-283.
37. Lebovitz HE. Clinician's manual on insulin resistance. London: Science Press; 2002.
38. Aguilar-Bryan L, Bryan J, Nakazaki M. Of mice and men: KATP channels and insulin secretion. Recent Prog Horm Res 2001;56:47-68.
39. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr Rev 1999;20:101-135.
40. Miki T, Nagashima K, Seino S. The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. . Mol Endocrinol 1999;22:113-123.
41. Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996;28:456-463.
42. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345-351.
43. Hu S, Wang S, Fanelli B, et al. Pancreatic D-cell KATP channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. . Pharmacol Exp Ther 2000;293:444-452.
44. Kahn SE, McCulloch DK, Porte D Jr. Insulin secretion in normal and diabetic humans. In: Alberti KGMM, Zimmet P, DeFronzo RA, Keen H, eds. International textbook of diabetes mellitus, 2nd ed. Chichester, UK: John Wiley & Sons, 1997:337.
45. Lebovitz HE. Insulin secretogogues: old and new. Diabetes Rev 1999;7: 139-153.
46. Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM, evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 1995;273:1855-1861.
47. Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical use. In: Alberti KGMM, Zimmet P, DeFronzo RA, Keen H, eds. International textbook of diabetes, 2nd ed. Chichester, UK: John Wiley & Sons, 1997:817.
48. Burge MR, Sood V, Sobhy TA, et al. Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. Diabetes Obes Metab 1999;1:199-206.
49. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989;18: 163-183.
50. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995;11: S57-S62.
51. Hu S, Wang S, Dunning BE. Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell KATP channels. . Pharmacol Exp Ther 1999;291:1372-1379.
52. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-336.
53. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012.
54. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303.
55. Rosenstock J, Schneider J, Samols E, et al. Glimepiride, a new once-daily sulfonylurea. Adouble-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996;19:1194-1199.
56. Chen HH, Oh KY, Terzic A, et al. The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure. Eur J Heart Fail 2000;2:33-40.
57. Cain BS, Meldrum DR, Meng X, et al. Exogenous calcium preconditions myocardium from patients taking oral sulfonylurea agents. . Surg Res 1999; 86:171-176.
58. Betteridge DJ, Close L. Diabetes, coronary heart disease and sulphonylureas-not the final word. Eur Heart J 2000;21:790-792.
59. Engler RL, Yallon DM. Sulfonylurea KATP blockade in type 2 diabetics and preconditioning in cardiovascular disease: time for reconsideration. Circulation 1996;94:2297-2301.
60. Shapiro ET, Van Cauter E, Tillil H, et al. Glyburide enhances the responsiveness of the beta cell to glucose but does not correct the abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. . Clin Endocrinol Metab 1989;69:571-576.
61. Van der Wal PS, Draeger KE, van Iperen AM, et al. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. Diabet Med 1997;14:556-563.
62. Stenman S, Melander A, Groop PH, et al. What is the benefit of increasing the sulphonylurea dose? Ann Intern Med 1993;118:169-172.
63. Wahlin-Boll E, Sartor G, Melander A, et al. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol 1982;22:21-25.
64. Kawaki J, Nagashima K, Tanaka J, et al. Unresponsiveness to glibenclamide during chronic treatment is induced by reduction of ATP-sensitive K+ channel activity. Diabetes 1999;48:2001-2006
65. Eliasson L, Renstrom E, Ammala C, et al. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic D'cells. Science 1996;771:813.
66. Clarke BF, Campbell IW. Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed maturity-onset diabetes. Lancet 1974;1:246.
67. Muller R, Bauer G, Schroder R, et al. Summary report of clinical investigation of the oral antidiabetic drug HB 419 (glibenclamide). Horm Metab Res 1969;1 [Suppl]:88.
68. Dills DG, Schneider J, Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996;28:426-429.
69. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983;24:412-417.
70. Shorr RI, Wayne RA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157:1681-1686.
71. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. . Am Geriatr Soc 1996;44:751-755.
72. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-741.
73. Berelowitz M, Schade DS, Fischette C, et al. Comparative efficacy of a oncedaily controlled-release formulation of glipizide and immediate release glipizide in patients with NIDDM. Diabetes Care 1994;17:1460-1464.
74. Simonson DC, Kourides IA, Fischette CT, et al. Glipizide GITS Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997;20:597-606.
75. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20:439-446.
76. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044-1052.
77. Draeger KE, Wemicke-Panten K, Lomp H-J, et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996;28:419-425.
78. Goldberg RB, Schneider J, Holvey SM, et al. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996;19:849-856.
79. Langtry HD, Balfour JA. Glimepiride: a review of its use in the management of type 2 diabetes. Drugs 1998;55:563-584.
80. Schneider J. An overview of the safety and tolerance of glimepiride. Horm Metab Res 1996;28:413-418.
81. Goldberg RB, Damsbo P, Einhorn D, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21: 1897-1903.
82. Jovanovic L, Dailey G III, Huang W-C, et al. Repaglinide in type 2 diabetes: a 24-week fixed-dose efficacy and safety study. . Clin Pharmacol 2000;40: 49-57.
83. Guay DRP. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus. Pharmacotherapy 1998;18:1195-1204.
84. Damsbo P, Marbury TC, Clauson P, et al. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999;22:789-794.
85. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001;61:1625-1660.
86. Marbury T, Huang W-C, Strange P, et al. Repaglinide versus glyburide: a one year comparison trial. Diabetes Res Clin Pract 1999;43:155-166.
87. Levien TL, Baker DE, Campbell RK, et al. Nateglinide therapy for type 2 diabetes mellitus. Ann Pharmacother 2001;35:1426-1434.
88. Walter YH, Spratt DI, Garreffa S, et al. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus. Eur J Clin Pharmacol 2000;56:129-133.
89. Horton ES, Foley J, Clinkingbeard C, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-1665.
90. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970;19[Suppl 2]:747-830.
91. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature 1983;305: 147-148.
92. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
93. Daut J, Maier-Rudolph W, vonBeckerath N, et al. Hypoxic dilatation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990; 247:1341-1344.
94. Cacciapuoti F, Spiezia R, Bianchi U, et al. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 1991;67:843-847.
95. Tomai F, Crea F, Gaspardone A, et al. Molecular and cellular responses: ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90:700-705.
96. Cleveland JC Jr, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revisited. Circulation 1997;96:29-32.
97. Garratt KN, Brady PA, Hassinger NL, et al.: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. . Am Coll Cardiol 1999;33:119-124.
98. Brooks RC, Detre KM. Clinical trials of revascularization in diabetics. Curr Opin Cardiol 2000;15:287-292.
99. Klamann A, Sarfert P, Launhardt V, et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000;21:220-229.
100. Buchanan TA, Xiang AH, Peters RK, et al. Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Diabetes 2001;50[Suppl 2]:327PP(abst).
101. Isomaa B, Almgren P, Henricsson M, et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999;22:1347-1353.
102. Ginsberg HN. Insulin resistance and cardiovascular disease. . Clin Invest 2000;6:453-458.
103. Lempiäinen P, Mykkänen L, Pyörälä K, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999;100:123-128.
104. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. . Engl J Med 2002;346:393-403.
105. Bell PM, Hadden DR. Metformin. Endocrinol Metab Clin North Am 1997;26: 523-537.
106. Bailey CJ, Turner RC. Drug therapy: metformin. . Engl J Med 1996;334: 574-579.
107. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999;58[Suppl 1]:31-39.
108. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type 2 diabetes mellitus. Diabetologia 1999;42:406-412.
109. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. . Engl J Med 1995;333:550-554.
110. Kurukulasuriya R, Banerji MA, Chaiden R, et al. Selective decrease in visceral fat is associated with weight loss during metformin treatment in African Americans with type 2 diabetes. Diabetes 1999;489[Suppl 1]:A315 (abst).
111. Yu JG, Kruszynska YT, Mulford MI, et al. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999;48:2414-2421.
112. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-2069.
113. Chu NV, Kong APS, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002;25:542-549.
114. Glucophage; Glucophage XR prescribing information. Bristol-Myers Squibb Co. Revised October 2000.
115. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-497.
116. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. . Engl J Med 1995;333:541-549.
117. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. BMJ 1977;2: 1576-1578.
118. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7 year follow-up. Clin Cardiol 2001;24:151-158.
119. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in type 2 diabetic patients using sulphonylurea and metformin in combination: a populationbased observational study. Diabetologia 2000;43:558-560.
120. Emslie-Smith AM, Boyle DI, Evans JM, et al. Contraindications to metformin therapy in patients with type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483-488.
121. Saleh YM, Mudaliar SR, Henry RP. Metabolic and vascular effects of the thiazolidinedione troglitazone. Diabetes Rev 1999;7:55-76.
122. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. . Engl J Med 1998;338:916-917.
123. Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:36-37.
124. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25:815-823.
125. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. . Med Chem 2000;43:527-550.
126. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor 'and metabolic disease. Annu Rev Biochem 2001;70:341-367.
127. Kliewer SA, Xu HE, Lambert MH, et al. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001;56:239-264.
128. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56:265-294.
129. Olefsky JM. Treatment of insulin resistance with peroxisome proliferatoractivated receptor 'agonists. . Clin Invest 2000;106:467-472.
130. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. . Clin Endocrinol Metab 2001;86:280-288.
131. Aranoff S, Mathisen AL, Rosenblatt S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000;23:1605-1611.
132. Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not the hypolipidemic effect of thiazolidinediones. . Clin Invest 2000;106:1221-1228.
133. Burant CF, Sreenan S, Hirano K, et al. Troglitazone action is independent of adipose tissue. . Clin Invest 1997;100:2900-2908.
134. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. . Clin Invest 1999;103:253-259.
135. Katsuki A, Murata K, Furuta M, et al. Troglitazone reduces plasma levels of tumour necrosis factor-'in obese patients with type 2 diabetes. Diabetes Obes Metab 2000;2:189-191.
136. Steppen CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
137. Yang W-S, Jeng C-Y, Wu T-J, et al. Synthetic peroxisome proliferator-activated receptor-'agonists, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25:376-380.
138. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. . Clin Invest 1998;101:1354-1361.
139. Montague CT, O'Rahilly S. The perils of portliness. Causes and consequences of visceral adiposity. Diabetes 2000;49:883-888.
140. Adams M, Montague CT, Prins JB, et al. Activators of PPAR'have depot-specific effects on human pre-adipocyte differentiation. . Clin Invest 1997;100: 3149-3153.
141. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999;57:921-930.
142. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000;60:333-343.
143. Khan MA, St Peter JV, Xue Jl. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25: 708-711.
144. Freed M, Fuell D, Menci L, et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia 2000;43[Suppl 1]:A267(abst).
145. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21: 2135-2139.
146. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802.
147. Lebovitz HE. Rationale for and role of thiazolidinediones in type 2 diabetes. Am J Cardiol 2002 (in press).
148. Finegood DT, McArthur MD, Kojwang D, et al. D-Cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021-1029.
149. Ghazzi M, Perez J, Antonucci T, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46:433-439.
150. Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000;23:1067-1071.
151. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR. Diabetes Care 2001;24:392-397.
152. Lebovitz HE. Oral antidiabetic agents. The emergence of -glucosidase inhibitors. Drugs 1992;44[Suppl 3]:21-28.
153. Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997;26:539-551.
154. Chiasson JL, Josse R, Hunt J, et al. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus. Ann Intern Med 1994; 121:928-935.
155. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years. Diabetes Care 1999;22:960-964.
156. Raskin P, Jovanovic L, Berger S, et al. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care 2000;23: 979-983.
157. Garber A, Davidson J, Mooradian A, et al. Effect of metformin/glyburide tablets on HbA1c in first-line treatment of type 2 diabetes. Diabetes 49[Suppl 1]:432-P, 2000(abst).
158. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;130:389-396.
159. Yki-Jarvinen H, Dressler A, Zieman M. Less nocturnal hypoglycemia and better post dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2001;23:1130-1136.
160. Raskin P, Rendell M, Riddle MC, et al. for the Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24: 1226-1232.
161. Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. . Engl J Med 1998;338:861-866.
162. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:182-188.
163. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. . Clin Endocrinol Metab 2001;86:3452-3456.